FBL13 Activators
F-box and leucine-rich repeat protein 13 (FBXL13) is a protein that is encoded by the FBXL13 gene in humans. It is a member of the F-box protein family, a diverse group of proteins that are characterized by the presence of an F-box, a motif of approximately 40 amino acids that has a key role in mediating protein-protein interactions.
F-box proteins, such as FBXL13, often function as part of a larger protein complex known as the SCF (SKP1-cullin-F-box) ubiquitin ligase complex. In this complex, the F-box proteins are responsible for substrate recognition. They bind to specific proteins, marking them for degradation by the ubiquitin-proteasome system. This system is a primary mechanism for protein turnover in cells, and is involved in numerous cellular processes, including cell cycle progression, signal transduction, and response to oxidative stress.The leucine-rich repeat (LRR) in FBXL13 is a motif that is frequently found in proteins and is known for its role in mediating protein-protein interactions. It likely contributes to the specific recognition and binding of substrate proteins by FBXL13.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
A proteasome inhibitor, potentially affecting the ubiquitin-proteasome pathway and indirectly influencing FBXL13 activity through altered protein degradation dynamics. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Another proteasome inhibitor, which might impact the ubiquitin-proteasome system and indirectly affect FBXL13 activity. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
A specific inhibitor of the proteasome, potentially influencing the ubiquitin-proteasome pathway and thereby affecting FBXL13 activity. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
A selective proteasome inhibitor, potentially affecting the ubiquitin-proteasome system and indirectly impacting FBXL13 activity. | ||||||
ATM/ATR Kinase Inhibitor Inhibitor | 905973-89-9 | sc-202964 | 5 mg | $106.00 | 8 | |
Inhibits the NEDD8-activating enzyme, affecting neddylation and potentially influencing the ubiquitin-proteasome system, thereby indirectly affecting FBXL13. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Affects lysosomal degradation pathways, which might indirectly influence FBXL13 activity by altering cellular protein degradation processes. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Modulates the ubiquitin-proteasome system, potentially impacting FBXL13 activity through its effects on protein degradation. | ||||||
Auranofin | 34031-32-8 | sc-202476 sc-202476A sc-202476B | 25 mg 100 mg 2 g | $153.00 $214.00 $4000.00 | 39 | |
Inhibits the proteasome, potentially impacting FBXL13 activity by altering protein degradation dynamics. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
A proteasome inhibitor, potentially influencing the ubiquitin-proteasome system and indirectly affecting FBXL13 activity. | ||||||